Welcome to our dedicated page for Aurinia Pharmaceuticals SEC filings (Ticker: AUPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Aurinia Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Aurinia Pharmaceuticals's regulatory disclosures and financial reporting.
Aurinia Pharmaceuticals Inc. (AUPH) is the subject of this Amendment No. 17 to a Schedule 13D filed by ILJIN SNT Co., Ltd., ILJIN Steel Co., Ltd., ILJIN GLS Co., Ltd. and related individuals. The filing reports that, following sales of Common Shares on August 20, 2026, the reporting group’s aggregate beneficial ownership of Aurinia’s Common Shares has fallen below 5% of the outstanding class, based on 133,051,168 shares outstanding as of August 5, 2026. As a result, the reporting persons state they will no longer be required to file beneficial ownership reports under Section 13(d) with respect to Aurinia’s Common Shares.
Aurinia Pharmaceuticals Inc. (AUPH) reported that Chief Legal Officer Stephen P. Robertson sold 20,975 shares of common stock on August 21, 2026 in a sale in the open market or a private transaction at a weighted average price of $16.97 per share. According to the company’s disclosure, these shares were automatically sold to cover tax withholding obligations arising from the vesting of Performance Stock Units related to a February 28, 2025 performance award. After this tax-related sale and including 360 shares acquired on May 29, 2026 under the 2021 Employee Share Purchase Plan, Robertson beneficially holds 600,787 common shares directly.
Aurinia Pharmaceuticals Inc. (AUPH) has a notice from officer Stephen P. Robertson indicating an intention under Rule 144 to sell up to 47,000 common shares through Morgan Stanley Smith Barney LLC on or after 08/21/2026 on NASDAQ. The shares relate to the vesting of performance stock units and are expected to be sold to satisfy associated tax withholding obligations.
Aurinia Pharmaceuticals Inc. (AUPH) reports that it and its U.S. subsidiary have entered into a settlement agreement with Teva Pharmaceuticals Inc. resolving U.S. patent litigation over Teva’s proposed generic 7.9 mg voclosporin oral capsules. Teva has stipulated that Aurinia’s U.S. Patent Nos. 10,286,036 and 11,622,991, which expire in December 2037, are enforceable, valid, and would be infringed by commercial sales of its generic product in the United States.
The settlement permits Teva to launch its generic voclosporin product in the United States no earlier than December 7, 2036, subject to defined contingencies and to obtaining FDA approval. Aurinia’s related patent infringement actions continue against several other generic manufacturers in the U.S. District Court for the District of New Jersey.
Aurinia Pharmaceuticals Inc. delivered higher profitability for the quarter ended June 30, 2026, driven by growth in LUPKYNIS. Net product sales were $79.4 million in the quarter and $153.0 million year‑to‑date, and diluted earnings per share reached $0.28 for the quarter.
Net income and operating cash flow both increased versus 2025, with cash flows from operating activities of $85.1 million for the first six months. Cash, cash equivalents, restricted cash and investments rose to $443.1 million, even after repurchasing 5.0 million common shares for $74.9 million.
Aurinia advanced its autoimmune pipeline by initiating PRESERVE, a Phase 4 study combining LUPKYNIS with several biologics in lupus nephritis, and by progressing aritinercept in four indications. It also completed an asset acquisition of Kezar Life Sciences, adding cash, in‑process R&D and a contingent value right structure.
Aurinia Pharmaceuticals Inc. reported strong financial results for the three and six months ended June 30, 2026. Total revenue reached $83.2 million for the quarter and $160.9 million year-to-date, up 19% and 21% from 2025, driven mainly by LUPKYNIS net product sales of $79.4 million and $153.0 million. Net income was $37.4 million for the quarter and $71.8 million for the first half, while diluted EPS rose to $0.28 and $0.53.
Cash flows from operating activities were $52.5 million in Q2 and $85.1 million for the first half, supporting cash, cash equivalents, restricted cash and investments of $443.1 million as of June 30, 2026. Aurinia repurchased 5.0 million common shares for $74.9 million. The company reiterated 2026 guidance for total revenue of $315 million to $325 million and LUPKYNIS net product sales of $305 million to $315 million. It also initiated PRESERVE, a Phase 4 study combining LUPKYNIS with biologic agents in lupus nephritis, and advanced aritinercept into clinical development in four potential autoimmune indications.
Aurinia Pharmaceuticals Inc. director Craig A. Johnson received a grant of stock options as part of his compensation. He was awarded 23,931 Director Stock Options, each giving the right to buy one common share at an exercise price of $15.67 per share.
The options vest one year from the grant date and expire on June 4, 2036. Following this grant, Johnson holds 23,931 options directly, with no open-market buying or selling reported in this filing.
Aurinia Pharmaceuticals director Kathleen Goetz received a grant of 23,931 Director Stock Options on June 4, 2026. These options give her the right to buy an equal number of common shares at an exercise price of 15.67 per share and expire on June 4, 2036.
The options were granted as compensation, not purchased in the market, and vest one year from the date of grant. Following this award, her reported derivative holdings from this grant total 23,931 options, all held directly.
Aurinia Pharmaceuticals Inc. reported that director Tina Susan Nova received a grant of stock options. The award covers 23,931 options to purchase common shares at an exercise price of $15.67 per share and is treated as a compensation grant, not a market purchase.
The options vest in full one year from the grant date and expire on June 4, 2036. Following this grant, Nova holds 23,931 derivative securities directly in the form of these options.
Aurinia Pharmaceuticals Inc. director Jeffrey Allen Bailey received a grant of stock options as part of his compensation. The award covers 23,931 options to purchase common shares at an exercise price of $15.67 per share. These options vest one year from the grant date and expire on June 4, 2036. Following this grant, Bailey holds 23,931 options directly, with no open-market purchases or sales reported in this filing.